Skip Navigation

Cardiovascular Research 2000 45(3):788-794; doi:10.1016/S0008-6363(99)00369-7
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Romeo, F.
Right arrow Articles by Mehta, J. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romeo, F.
Right arrow Articles by Mehta, J. L
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells*

modulation of Fas/Fas ligand and caspase-3 pathway

Frencesco Romeoa, Dayuan Lib, Min Shib and Jawahar L Mehtab,*

aDepartment of Cardiology, Second University, Rome, Italy
bDepartments of Medicine and Physiology, University of Florida College of Medicine and VA Medical Center, 1600 Archer Rd., P.O. Box 100277 JHMHC, Gainesville, FL 32610, USA

* Corresponding author. Tel.: +1-352-370-4160; fax: +1-352-379-4161 mehta{at}medmac.ufl.edu

Background: Several studies have shown that carvedilol, a multiple action neurohumoral antagonist, reduces mortality in patients with congestive heart failure (CHF). In addition to being a β-adrenoceptor antagonist, carvedilol is a potent antioxidant. Since there is evidence for elevation of catecholamine levels in plasma and coronary artery endothelial cell injury in CHF, the present study was designed to test the hypothesis that carvedilol inhibits epinephrine-induced apoptosis, and the inhibitory effect is mediated by modulation of Fas, Fas ligand (FasL) and caspase-3 pathway, in cultured human coronary artery endothelial cells (HCAECs). Methods and results: HCAECs were exposed to epinephrine alone, carvedilol+epinephrine, or atenolol+epinephrine for 24 h. Epinephrine increased the number of apoptotic cells, measured by in situ nick end-labeling staining (from 4.2±1.3% to 28.6±6.0%, P<0.01, n=6) and by DNA laddering on agarose gel electrophoresis. Epinephrine also increased Fas and FasL protein expression (P<0.01 vs. control, n=6), and activated intracellular protease caspase-3 (P<0.01 vs. control, n=6). These effects of epinephrine were completely inhibited by carvedilol. Atenolol in equimolar concentration also attenuated epinephrine-mediated effects, but the effects of atenolol were less marked than those of carvedilol (P<0.01). To explore the basis of differential effects of carvedilol and atenolol, effects of these agents on epinephrine-induced lipid peroxidation was measured. Lipid peroxidation was completely blocked by carvedilol, whereas equimolar concentration of atenolol had much less (P<0.05) effect. Conclusion: Epinephrine induces apoptosis in HCAECs, and this effect is associated with activation of Fas–FasL and caspase-3 signal transduction pathway. Carvedilol can, more effectively than atenolol, inhibit these effects of epinephrine. The potent antioxidant effect of carvedilol is probably responsible for the superior effect.

KEYWORDS Adrenergic (ant)agonists; Apoptosis; Endothelial function; Free radicals


* Supported by a Merit Review Award from the VA Central Office and funds from Smith Kline Beecham, Philadelphia, PA, USA.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
G. Cioffi, L. Tarantini, S. De Feo, G. Pulignano, D. Del Sindaco, C. Stefenelli, and C. Opasich
Pharmacological left ventricular reverse remodeling in elderly patients receiving optimal therapy for chronic heart failure
Eur J Heart Fail, October 1, 2005; 7(6): 1040 - 1048.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.